THE BINDING OF [3H]-OESTRADIOL-17β IN THE IMMATURE RAT UTERUS DURING THE SEQUENTIAL ADMINISTRATION OF NONSTEROIDAL ANTI-OESTROGENS
- 1 February 1979
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 65 (2), 167-173
- https://doi.org/10.1111/j.1476-5381.1979.tb07815.x
Abstract
1 The binding of [(3)H]-oestradiol-17beta (0.08 mug) in the uterus, vagina, liver and heart of immature female rats has been studied in vivo and the effect of daily administrations of the non-steroidal anti-oestrogens, tamoxifen and monohydroxytamoxifen, on the 2 h accumulation of [(3)H]-oestradiol-17beta in the uterus has been determined.2 Doses of tamoxifen (8 mug daily) or monohydroxytamoxifen (1.28 mug daily), which have previously been found to antagonize completely the uterotrophic activity of oestradiol-17beta (0.08 mug daily), did not significantly reduce the total uterine binding of 0.08 mug [(3)H]-oestradiol-17beta administered on day 4 of a 3-day uterine weight test.3 The simultaneous administration of tamoxifen (8 mug) or monohydroxytamoxifen (1.28 mug) with [(3)H]-oestradiol-17beta (0.08 mug) on day 3 of a uterine weight test did not significantly reduce the total uterine binding of oestradiol-17beta. The binding of [(3)H]-oestradiol-17beta was reduced if monohydroxytamoxifen or tamoxifen was administered 4 h before the oestradiol.4 Tamoxifen (8 mug daily) or monohydroxytamoxifen (1.28 mug daily) did not prevent the translocation of [(3)H]-oestradiol (0.08 mug) to the uterine cell nucleus on day 3 of a 3-day uterine weight test.5 The measurement of total nuclear oestrogen receptors by an exchange assay technique demonstrated a higher concentration of oestrogen receptors in anti-oestrogen-treated animals compared with controls.6 Since the administration of anti-oestrogenic doses of non-steroidal anti-oestrogens during a 3-day uterine weight test did not inhibit the total binding of oestradiol in the uterus, or affect the translocation of the steroid to the nucleus, the mechanism of action of non-steroidal anti-oestrogens over the range of the partial agonist dose-response curve must involve an interaction, or competition of oestradiol-17beta- and anti-oestrogen-oestrogen receptor complexes for sites within the nucleus.Keywords
This publication has 34 references indexed in Scilit:
- Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomataEuropean Journal of Cancer (1965), 1976
- TAMOXIFEN AS AN ANTI-TUMOUR AGENT: OESTROGEN BINDING AS A PREDICTIVE TEST FOR TUMOUR RESPONSEJournal of Endocrinology, 1976
- TAMOXIFEN AS AN ANTI-TUMOUR AGENT: ROLE OF OESTRADIOL AND PROLACTINJournal of Endocrinology, 1976
- TAMOXIFEN AS AN ANTI-TUMOUR AGENT: EFFECT ON OESTROGEN BINDINGJournal of Endocrinology, 1976
- In vivo effect of anti-estrogens on the localisation and replenishment of estrogen receptorMolecular and Cellular Endocrinology, 1975
- Modulation of uterine morphology and growth by estradiol-17beta and an estrogen antagonist.The Journal of cell biology, 1975
- Oestrogen receptors and antagonism of steroid hormone actionNature, 1974
- Estrogen receptor · anti-estrogen complex: Atypical binding by uterine nuclei and effects on uterine growthSteroids, 1973
- Control of estrogen binding protein concentration under basal conditions and after estrogen administrationBiochemistry, 1971
- Control by Estrogen of Genetic Transcription and TranslationScience, 1968